Biodexa Pharmaceuticals (STU:5MP2) Interest Expense: €-0.27 Mil (TTM As of Dec. 2025)

What is Biodexa Pharmaceuticals Interest Expense?

Biodexa Pharmaceuticals STU:5MP2 10 Interest Expense is €-0.27 Mil as of Dec. 2025. GuruFocus rates STU:5MP2 with a GF Score™ of 10/100 and a GF Value™ of €95,593.41.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Biodexa Pharmaceuticals's interest expense for the six months ended in Dec. 2025 was € -0.11 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.27 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Biodexa Pharmaceuticals's Operating Income for the six months ended in Dec. 2025 was € -5.29 Mil. Biodexa Pharmaceuticals's Interest Expense for the six months ended in Dec. 2025 was € -0.11 Mil. Biodexa Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Biodexa Pharmaceuticals (STU:5MP2) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Biodexa Pharmaceuticals's Interest Expense for the six months ended in Dec. 2025 was €-0.11 Mil. Its Operating Income for the six months ended in Dec. 2025 was €-5.29 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2025 was €0.00 Mil.

Biodexa Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Biodexa Pharmaceuticals did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Biodexa Pharmaceuticals Interest Expense Historical Data

* Premium members only.

The historical data trend for Biodexa Pharmaceuticals's Interest Expense can be seen below:

Biodexa Pharmaceuticals Interest Expense Chart

Biodexa Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Interest Expense

Get a 7-Day Free Trial

-0.05

-0.06

-0.05

-0.20

-0.26

Biodexa Pharmaceuticals Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
Interest Expense	Get a 7-Day Free Trial															-0.02	-0.06	-0.14	-0.16	-0.11

10GF Score

Biodexa Pharmaceuticals PLC STU:5MP2

Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Biodexa Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.27 Mil.

Frequently Asked Questions Learn more about Interest Expense →

What does a Interest Expense of €-0.27 Mil mean?

Biodexa Pharmaceuticals (STU:5MP2) has a Interest Expense of €-0.27 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Biodexa Pharmaceuticals and its competitors.

Is Biodexa Pharmaceuticals' Interest Expense too high?

Biodexa Pharmaceuticals' current Interest Expense is €-0.27 Mil. Overall, Biodexa Pharmaceuticals has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.

How does Biodexa Pharmaceuticals' Interest Expense compare to CASIF and OGEN?

Biodexa Pharmaceuticals' Interest Expense of €-0.27 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Interest Expense for a Biotechnology company?

A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Interest Expense mean?

A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Biodexa Pharmaceuticals and its competitors. Biodexa Pharmaceuticals's current Interest Expense is €-0.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Biodexa Pharmaceuticals stock overvalued right now?

Biodexa Pharmaceuticals (STU:5MP2) has a current Interest Expense of €-0.27 Mil. The stock's GF Value™ is €95,593.41, compared to a current price of €110,400.00 — trading 15.5% above its estimated fair value. The current Interest Expense is €-0.27 Mil. Biodexa Pharmaceuticals' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Interest Expense calculated?

Interest Expense is calculated from a company's financial statements. For Biodexa Pharmaceuticals (STU:5MP2), the current Interest Expense is €-0.27 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biodexa Pharmaceuticals (STU:5MP2) Overvalued in 2026?

Based on GuruFocus' analysis, Biodexa Pharmaceuticals stock appears to be overvalued. The current stock price of €110,400.00 is trading 15.5% above its estimated GF Value™ of €95,593.41.

Key valuation signals for STU:5MP2:

Interest Expense: €-0.27 Mil
GF Value™: €95,593.41 vs. price of €110,400.00 (15.5% above fair value)
GF Score™: 10/100

No single metric tells the full story. See the STU:5MP2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biodexa Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies CASIF OGEN ELOX CPMV VBIO JAGX BBLG PKTX SLXN HEPA VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges BDRX:USA

Address 1 Caspian Point, Caspian Way, Cardiff, GBR, CF10 4DQ

Website https://www.biodexapharma.com

Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.

10GF Score

Get the complete analysis for STU:5MP2

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€110,400.00

Price

€95,593.41

GF Value

View STU:5MP2 Analysis

See Interest Expense data for all stocks →